ArticleJournal of virology2025
A novel replication-deficient FCV vaccine provides strong immune protection in cats.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Isolation, Molecular Characterization, and Pathogenicity Evaluation of a Genotype GI Feline Calicivirus Isolate.Microorganisms · 2026Article
- Isolation of feline-derived scFvs against the VP1-CDE region of feline calicivirus from a phage display library and characterization of their antigen-binding and antiviral potential in vitro.BMC veterinary research · 2026Article
- A novel replication-deficient feline herpesvirus type 1 vector-based vaccine provides strong immune protection in cats.Journal of virology · 2026Article
- Evaluating Neutralizing Antibody Titers by Recombinant Feline Calicivirus with Heterologous Capsid Protein VP1.Animals : an open access journal from MDPI · 2026Article
- Feline calicivirus VP1-based mRNA vaccine protects cats against FCV challenge.Virologica Sinica · 2026Article
- Construction of Reverse Genetics System for Feline Calicivirus FCV-BJ616 and Proteomic Analysis.MicrobiologyOpen · 2026Article
- Development and Application of a Blocking ELISA for the Detection of Feline Calicivirus Antibodies Based on Monoclonal Antibodies Against VP1 Protein.Transboundary and emerging diseases · 2026Article
- A Virulent Systemic Feline Calicivirus Strain Isolated in China Could Produce Broadly Neutralizing Antibodies Against Multiple Strains.Transboundary and emerging diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Feline calicivirus (FCV) belongs to the family Caliciviridae, which includes important animal and human pathogens such as human norovirus and rabbit hemorrhagic disease virus. The fast evolution and great diversity of FCV make it highly difficult to develop vaccines that can induce sterilizing immunity. In this study, we evaluated the efficacy of a vaccine candidate generated via a replication-deficient vaccine strategy. Immunization with the vaccine generated a high level of neutralizing antibodies and highly reduced clinical outcomes against the challenge with a homologous virulent systemic feline calicivirus (VS-FCV) strain. Moreover, the VP1 gene of the vaccine was replaced with that derived from a heterologous virus strain. Vaccination with two combined virus constructs containing genetically distant VP1 genes led to the generation of broad neutralizing antibodies against FCV strains in cats. Notably, this replication-deficient FCV has the potential to serve as a viral vector vaccine, enabling the delivery of a foreign gene with stable genetics. In summary, this vaccine strategy holds great promise for developing safe, effective, and multivalent vaccines to prevent and control calicivirus infection.IMPORTANCEFCV is one of the leading causes of respiratory diseases in cats. Over the last 20 years, certain strains evolved into VS-FCV, with severe symptoms and increased fatality. Updating and developing vaccines promptly are essential. Here, we employed reverse genetics to partially delete the VP2 gene of FCV, rescuing the replication-deficient vaccine candidate rHBDL2 FCV-△VP2. Immunization with this candidate generated high levels of neutralizing antibodies against FCV strains and significantly reduced clinical symptoms. Furthermore, the adaptability of this replication-defective FCV platform holds potential for the development of viral vector vaccines as well as multivalent vaccines, which are also crucial for the prevention and control of other calicivirus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.